We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0K9E market cap is 151.67B. The company's latest EPS is USD 6.0458 and P/E is 17.73.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 49.9B | 52.88B | 51.83B | 54.11B | 51.72B |
| Operating Income | 10.83B | 27.03B | 9.19B | 10.02B | 14.51B |
| Net Income | 8.07B | 24.02B | 6.96B | 14.85B | 11.94B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 132.06B | 131.8B | 117.45B | 99.95B | 102.25B |
| Total Liabilities | 75.39B | 63.97B | 58.03B | 53.2B | 58.12B |
| Total Equity | 56.67B | 67.82B | 59.42B | 46.75B | 44.13B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 13.65B | 15.07B | 14.24B | 9.84B | 17.62B |
| Investing | -13.18B | 4.21B | 1.47B | N/A | -7.51B |
| Financing | -2.21B | -16.26B | -20.56B | N/A | -11.74B |
| Market Cap | 151.67B |
| Price to Earnings Ratio | 17.73 |
| Price to Sales Ratio | 4.09 |
| Price to Cash Ratio | 18.48 |
| Price to Book Ratio | 4.8 |
| Dividend Yield | - |
| Shares Outstanding | 1.98B |
| Average Volume (1 week) | 106 |
| Average Volume (1 Month) | 415 |
| 52 Week Change | 0.00% |
| 52 Week High | 76.79 |
| 52 Week Low | 76.79 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Novartis Ag |
| Address |
po box basel 4002 |
| Website | https://www.novartis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
